IsomAb
Business Services · United Kingdom · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Biocity Nottingham Innovation Building P...Website
isomab.bioRevenue
$5.1 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About IsomAb
IsomAb is taking a different approach to identify, evaluate and develop isoform specific antibodies to treat disease where patients currently have limited or no treatment options. IsomAb is developing isoform specific antibodies and it has identified, using a combined bioinformatics/knowledge-based platform approach, ISM-001 which specifically inhibits the VEGF-A165b isoform of Vascular Endothelial Growth Factor-A (VEGF-A); based on 20 years of research by the company's two Founders, the evidence shows reducing serum levels of VEGF-A165b is key to ensuring new blood vessel formation in patients with ischemic disease.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is IsomAb your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once IsomAb has new funding data
Check if IsomAb has recently received funding, and reach out quickly before it becomes old news!
IsomAb, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at IsomAb
Click to see if IsomAb had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when IsomAb launches new products
Check out if IsomAb is spiking on competitors!
Earning: See what the market has to say on IsomAb recently announced quarterly report
Recommended Actions
Find VP level buyers at IsomAb
Find 2 more new buyers
Compare Similar Companies to IsomAb
Compare insights from companies similar to IsomAb, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
IsomAb
$5.1M
11-50
Private
$9.5M
2022
N/A
IsomAb financials insights
Gather financial insights about IsomAb, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2024
Other Financing Round
$9.5M
Most Recent Scoops
New Hire
Executive Move
Executive Moves, New Hire, Board of Directors
Executive Move
Executive Moves, Board of Directors
Executive Move
Executive Moves, Board of Directors
Event
Person-Based
Harry Destecroix, Non Executive Director, appeared on a podcast called "The Bottom Line" on 10/02/2025. Topics discussed include University research, spin-outs, business creation.
Events, Podcast
New Hire
Executive Move
Executive Moves, New Hire
IsomAb News & Media
IsomAb makes two key appointments; Dr Shi Yin Foo M.D. as Non-Executive Director and Dr Gary Burgess M.D. as Chief Medical Officer
Aim to accelerate progress of lead candidate ISM-001 for peripheral ischaemia to clinic NOTTINGHAM, England, Feb. 25, 2025 /PRNewswire/ -- IsomAb Ltd, a UK-based biotechnology company developing novel isoform-specific disease modifying antibody treatments, for peripheral arterial disease...Fundraising: Cambridge life science cluster a honeypot for global backers
Cambridge life science companies raised a combined $1.341 billion over the last 12 months (to October 16, 2024) with 17 of the 19 biggest hauls backed by investors from the United States and two notable seed rounds each worth well over $10 million.IsomAb Announces Nomination of Development Candidate for Peripheral Arterial Disease and Strategic Collaboration with Pfizer
ISM-001 is a potential first-in-class antibody that may lead to a new treatment pathway for patients with peripheral arterial disease (PAD) Company enters strategic collaboration with Pfizer Ignite to accelerate IND-enabling regulatory studies NOTTINGHAM, England, Oct. 15, 2024...
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding IsomAb
Sign Up For FreeTo access detailed company insights
IsomAb is taking a different approach to identify, evaluate and develop isoform specific antibodies to treat disease where patients currently have limited or no treatment options. IsomAb is developing isoform specific antibodies and it has identified, using a combined bioinformatics/knowledge-based platform approach, ISM-001 which specifically inhi... Read More
